• Species Reactivity
  Human
• Specificity
  Detects human Integrinbeta 6 in direct ELISAs.
• Source
  Monoclonal Mouse IgG_2B Clone # 437211
• Purification
  Protein A or G purified from hybridoma culture supernatant
• Immunogen
  Chinese hamster ovary cell line CHO-derived recombinant human Integrin alpha V beta 6
  Phe31-Val992 (Integrinalpha V) and Gly22-Asn707 (Integrinbeta 6)
  Accession # P18564
• Formulation
  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Label
  Unconjugated

• Flow Cytometry
  0.25 µg/10⁶ cells
  See below
• CyTOF-ready
  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
• Immunocytochemistry
  8-25 µg/mL
  See below

• Reconstitution
  Reconstitute at 0.5 mg/mL in sterile PBS.
• Shipping
  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
• Stability & Storage
  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

• Entrez Gene IDs:
  3694 (Human); 16420 (Mouse); 311061 (Rat)
• Alternate Names:
  Integrin beta 6; integrin beta-6; integrin, beta 6; ITGB6

Background:

Integrin beta 6 (ITG beta 6) is a 95 kDa member of the Integrin beta family. It forms noncovalent heterodimers with Integrinalpha V and appears on epithelia following injury or inflammation. It activates TGF-betaand assists keratinocyte migration. Human Integrin beta 6 is a type I transmembrane glycoprotein that is 767 aa in length. It contains a 688 aa extracellular domain (ECD) (aa 22‑709) that incorporates a 241 aa VWF-A domain. Over aa 22‑707, human integrin beta 6 ECD shares 90% and 93% aa sequence identity with mouse and pig integrin beta 6 ECD, respectively.

      R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。